Duvelisib is a medication that belongs to a class of drugs known as phosphoinositide 3-kinase (PI3K) inhibitors. It is used in the treatment of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Duvelisib works by blocking the activity of PI3K enzymes, which are involved in the growth and survival of cancer cells.

This medication is typically prescribed for patients who have not responded well to other treatments or who have relapsed after previous therapies. Duvelisib can be taken orally in the form of capsules, usually once or twice daily as directed by a healthcare provider.

As with any medication, there are potential side effects associated with duvelisib. Common side effects may include diarrhea, nausea, fatigue, and respiratory infections. It is important to report any unusual or severe side effects to your healthcare provider promptly.

Before starting duvelisib, it is important to inform your healthcare provider about any other medications you are taking, as well as any medical conditions you may have. This will help ensure that duvelisib is safe and appropriate for you.

Overall, duvelisib has shown promising results in the treatment of CLL and SLL, offering a new option for patients who may not have responded well to other therapies. If you have been prescribed duvelisib, it is important to follow your healthcare provider’s instructions carefully and to communicate any concerns or questions you may have. Your healthcare team is here to support you throughout your treatment journey.